Feng Yue named director for cancer genomics at Lurie Cancer Center

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Feng Yue was appointed director of the Center for Cancer Genomics of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.

Yue joins Northwestern from the Penn State College of Medicine, where he was director of bioinformatics in the Penn State Institute for Personalized Medicine. His research focuses on how genetic variants contribute to gene regulation and three-dimensional organization of DNA molecules that influence human diseases.

He was recruited in a joint effort with the department of biochemistry and molecular genetics, the Simpson Querrey Center for Epigenetics, and the Center for Genetic Medicine, and will join Northwestern this summer. His hiring will advance basic, translational and clinical research in cancer genomics, and promote data sharing across disciplines.

“The recruitment of Feng Yue will dramatically impact our research efforts,” Leonidas Platanias, director of the Lurie Cancer Center and the Jesse, Sara, Andrew, Abigail, Benjamin and Elizabeth Lurie Professor of Oncology, said in a statement. “We are poised to maximize the potential of cancer genomics and accelerate its translation to precision oncology and individually tailored therapies.”

Yue received his postdoctoral training at the Ludwig Institute for Cancer Research, UCSD School of Medicine.

Table of Contents

YOU MAY BE INTERESTED IN

When our hematological malignancy testing pilot project began in Eldoret, Kenya, there seemed to be a mismatch in relation to progress in healthcare. The region, like much of sub-Saharan Africa, had been focusing on combatting infectious diseases such as HIV and malaria—which was much-needed—yet cancer care was under-resourced. 
Artificial intelligence is rapidly transforming biomedical research and healthcare. Large language models, foundation models, and AI agents are increasingly being deployed to assist with data interpretation, literature review, clinical decision support, and translational research. 
In modern oncology, important insights from clinical trials often emerge years after initial publication. As new therapies extend survival and transition more patients into long-term remissions, clinicians and researchers are increasingly looking beyond initial response rates to understand durability, long-term safety, and even the possibility of a cure. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login